{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1362825896002602368.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1161/hypertensionaha.107.108845"}},{"identifier":{"@type":"URI","@value":"https://www.ahajournals.org/doi/full/10.1161/HYPERTENSIONAHA.107.108845"}}],"dc:title":[{"@value":"Effects of Aliskiren on Blood Pressure, Albuminuria, and (Pro)Renin Receptor Expression in Diabetic TG(mRen-2)27 Rats"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:p>\n            The aim of this study was to explore the effects of the renin inhibitor aliskiren in streptozotocin-diabetic TG(mRen-2)27 rats. Furthermore, we investigated in vitro the effect of aliskiren on the interactions between renin and the (pro)renin receptor and between aliskiren and prorenin. Aliskiren distributed extensively to the kidneys of normotensive (non)diabetic rats, localizing in the glomeruli and vessel walls after 2 hours exposure. In diabetic TG(mRen-2)27 rats, aliskiren (10 or 30 mg/kg per day, 10 weeks) lowered blood pressure, prevented albuminuria, and suppressed renal transforming growth factor-β and collagen I expression versus vehicle. Aliskiren reduced (pro)renin receptor expression in glomeruli, tubules, and cortical vessels compared to vehicle (in situ hybridization). In human mesangial cells, aliskiren (0.1 μmol/L to 10 μmol/L) did not inhibit binding of\n            <jats:sup>125</jats:sup>\n            I-renin to the (pro)renin receptor, nor did it alter the activation of extracellular signal-regulated kinase 1/2 by renin (20 nmol/L) preincubated with aliskiren (100 nmol/L) or affect gene expression of the (pro)renin receptor. Evidence was obtained that aliskiren binds to the active site of prorenin. The above results demonstrate the antihypertensive and renoprotective effects of aliskiren in experimental diabetic nephropathy. The evidence that aliskiren can reduce in vivo gene expression for the (pro)renin receptor and that it may block prorenin-induced angiotensin generation supports the need for additional work to reveal the mechanism of the observed renoprotection by this renin inhibitor.\n          </jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1382825896002602246","@type":"Researcher","foaf:name":[{"@value":"David L. Feldman"}],"jpcoar:affiliationName":[{"@value":"From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Médecine Expérimentale (A.C., G.N.), Collège de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands."}]},{"@id":"https://cir.nii.ac.jp/crid/1382825896002602241","@type":"Researcher","foaf:name":[{"@value":"Liang Jin"}],"jpcoar:affiliationName":[{"@value":"From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Médecine Expérimentale (A.C., G.N.), Collège de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands."}]},{"@id":"https://cir.nii.ac.jp/crid/1382825896002602368","@type":"Researcher","foaf:name":[{"@value":"Hong Xuan"}],"jpcoar:affiliationName":[{"@value":"From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Médecine Expérimentale (A.C., G.N.), Collège de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands."}]},{"@id":"https://cir.nii.ac.jp/crid/1382825896002602245","@type":"Researcher","foaf:name":[{"@value":"Aurelie Contrepas"}],"jpcoar:affiliationName":[{"@value":"From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Médecine Expérimentale (A.C., G.N.), Collège de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands."}]},{"@id":"https://cir.nii.ac.jp/crid/1382825896002602369","@type":"Researcher","foaf:name":[{"@value":"Yinong Zhou"}],"jpcoar:affiliationName":[{"@value":"From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Médecine Expérimentale (A.C., G.N.), Collège de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands."}]},{"@id":"https://cir.nii.ac.jp/crid/1382825896002602249","@type":"Researcher","foaf:name":[{"@value":"Randy L. Webb"}],"jpcoar:affiliationName":[{"@value":"From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Médecine Expérimentale (A.C., G.N.), Collège de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands."}]},{"@id":"https://cir.nii.ac.jp/crid/1382825896002602243","@type":"Researcher","foaf:name":[{"@value":"Dominik N. Mueller"}],"jpcoar:affiliationName":[{"@value":"From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Médecine Expérimentale (A.C., G.N.), Collège de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands."}]},{"@id":"https://cir.nii.ac.jp/crid/1382825896002602250","@type":"Researcher","foaf:name":[{"@value":"Sandra Feldt"}],"jpcoar:affiliationName":[{"@value":"From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Médecine Expérimentale (A.C., G.N.), Collège de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands."}]},{"@id":"https://cir.nii.ac.jp/crid/1382825896002602242","@type":"Researcher","foaf:name":[{"@value":"Frederick Cumin"}],"jpcoar:affiliationName":[{"@value":"From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Médecine Expérimentale (A.C., G.N.), Collège de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands."}]},{"@id":"https://cir.nii.ac.jp/crid/1382825896002602240","@type":"Researcher","foaf:name":[{"@value":"Wieslawa Maniara"}],"jpcoar:affiliationName":[{"@value":"From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Médecine Expérimentale (A.C., G.N.), Collège de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands."}]},{"@id":"https://cir.nii.ac.jp/crid/1382825896002602247","@type":"Researcher","foaf:name":[{"@value":"Elke Persohn"}],"jpcoar:affiliationName":[{"@value":"From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Médecine Expérimentale (A.C., G.N.), Collège de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands."}]},{"@id":"https://cir.nii.ac.jp/crid/1382825896002602244","@type":"Researcher","foaf:name":[{"@value":"Helmut Schuetz"}],"jpcoar:affiliationName":[{"@value":"From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Médecine Expérimentale (A.C., G.N.), Collège de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands."}]},{"@id":"https://cir.nii.ac.jp/crid/1382825896002602370","@type":"Researcher","foaf:name":[{"@value":"A.H. Jan Danser"}],"jpcoar:affiliationName":[{"@value":"From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Médecine Expérimentale (A.C., G.N.), Collège de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands."}]},{"@id":"https://cir.nii.ac.jp/crid/1382825896002602248","@type":"Researcher","foaf:name":[{"@value":"Genevieve Nguyen"}],"jpcoar:affiliationName":[{"@value":"From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Médecine Expérimentale (A.C., G.N.), Collège de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands."}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"0194911X"},{"@type":"EISSN","@value":"15244563"}],"prism:publicationName":[{"@value":"Hypertension"}],"dc:publisher":[{"@value":"Ovid Technologies (Wolters Kluwer Health)"}],"prism:publicationDate":"2008-07","prism:volume":"52","prism:number":"1","prism:startingPage":"130","prism:endingPage":"136"},"reviewed":"false","url":[{"@id":"https://www.ahajournals.org/doi/full/10.1161/HYPERTENSIONAHA.107.108845"}],"createdAt":"2008-05-20","modifiedAt":"2024-05-13","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360004234890435968","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004236436191616","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Plasma Soluble (Pro)Renin Receptor Is Independent of Plasma Renin, Prorenin, and Aldosterone Concentrations But Is Affected by Ethnicity"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285707402757120","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Expression of (pro)renin receptor and its upregulation by high salt intake in the rat nephron"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168684734976","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Hemodynamic and Hormonal Changes to Dual Renin–Angiotensin System Inhibition in Experimental Hypertension"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567185700571392","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Effects of Aliskiren‐Based Therapy on Ambulatory Blood Pressure Profile, Central Hemodynamics, and Arterial Stiffness in Nondiabetic Mild to Moderate Hypertensive Patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848658394795008","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Greater reductions in plasma aldosterone with aliskiren in hypertensive patients with higher soluble (Pro)renin receptor level"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848664422074112","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Addition of Aliskiren to Angiotensin Receptor Blocker Improves Ambulatory Blood Pressure Profile and Cardiorenal Function Better than Addition of Benazepril in Chronic Kidney Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001277344927744","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Zhengganxifeng Decoction Affects Gut Microbiota and Reduces Blood Pressure <i>via</i> Renin–Angiotensin System"},{"@value":"Zhengganxifeng Decoction Affects Gut Microbiota and Reduces Blood Pressure via Renin-Angiotensin System"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679252924800","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"The pharmacological profile and clinical findings on aliskiren (Rasilez tablet), direct renin inhibitor"},{"@language":"ja","@value":"直接的レニン阻害薬アリスキレン（ラジレス）の薬理学的特長および臨床試験成績"},{"@value":"新薬紹介総説 直接的レニン阻害薬アリスキレン(ラジレス)の薬理学的特長および臨床試験成績"},{"@language":"ja-Kana","@value":"シンヤク ショウカイ ソウセツ チョクセツテキ レニン ソガイヤク アリスキレン ラジレス ノ ヤクリガクテキ トクチョウ オヨビ リンショウ シケン セイセキ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282680156305536","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"New Approaches to Blockade of the Renin-Angiotensin-Aldosterone System: Characteristics and Usefulness of the Direct Renin Inhibitor Aliskiren"},{"@value":"Characteristics and usefulness of the direct renin inhibitor aliskiren"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282681411157120","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"レニン阻害剤"},{"@language":"en","@value":"Calcium Channel BlockersDirect Renin Inhibitors (DRI) as Novel Antihypertensive Agents"},{"@language":"ja-Kana","@value":"レニン ソガイザイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282681423734272","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"2. Renoprotective Effects of Novel Drugs"},{"@language":"ja","@value":"2．新規薬剤における腎保護作用"},{"@value":"新規薬剤における腎保護作用"},{"@language":"ja-Kana","@value":"シンキ ヤクザイ ニ オケル ジンホゴ サヨウ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390564238096747776","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"RENIN ANGIOTENSIN SYSTEM-DEPENDENT AND -INDEPENDENT FUNCTIONS OF (PRO)RENIN RECEPTOR AND THE ROLES OF ITS BLOCKERS"}]},{"@id":"https://cir.nii.ac.jp/crid/2050870367074157184","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Renin inhibition ameliorates renal damage through prominent suppression of both angiotensin Ⅰ and Ⅱ in human renin angiotensinogen transgenic mice with high salt loading"}]},{"@id":"https://cir.nii.ac.jp/crid/2051151842050541312","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Local delivery of a direct renin inhibitor into the kidney ameliorates progression of experimental glomerulonephritis"}]},{"@id":"https://cir.nii.ac.jp/crid/2051151842052969216","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Arterial wall hypertrophy is ameliorated by α2-adrenergic receptor antagonist or aliskiren in kidneys of angiotensinogen-knockout mice"}]},{"@id":"https://cir.nii.ac.jp/crid/2051996266980980864","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Serum level of soluble (pro)renin receptor is modulated in chronic kidney disease"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1161/hypertensionaha.107.108845"},{"@type":"CROSSREF","@value":"10.2169/naika.101.1347_references_DOI_PWDbkUTySA9tl5S0HNPCLnxAuN2"},{"@type":"CROSSREF","@value":"10.1007/s10157-012-0601-y_references_DOI_PWDbkUTySA9tl5S0HNPCLnxAuN2"},{"@type":"CROSSREF","@value":"10.1254/fpj.135.159_references_DOI_PWDbkUTySA9tl5S0HNPCLnxAuN2"},{"@type":"CROSSREF","@value":"10.1007/s10157-017-1520-8_references_DOI_PWDbkUTySA9tl5S0HNPCLnxAuN2"},{"@type":"CROSSREF","@value":"10.1111/j.1751-7176.2012.00640.x_references_DOI_PWDbkUTySA9tl5S0HNPCLnxAuN2"},{"@type":"CROSSREF","@value":"10.1016/j.peptides.2014.12.007_references_DOI_PWDbkUTySA9tl5S0HNPCLnxAuN2"},{"@type":"CROSSREF","@value":"10.1254/jphs.10r04fm_references_DOI_PWDbkUTySA9tl5S0HNPCLnxAuN2"},{"@type":"CROSSREF","@value":"10.7831/ras.2.37_references_DOI_PWDbkUTySA9tl5S0HNPCLnxAuN2"},{"@type":"CROSSREF","@value":"10.1161/hypertensionaha.112.201889_references_DOI_PWDbkUTySA9tl5S0HNPCLnxAuN2"},{"@type":"CROSSREF","@value":"10.1161/hypertensionaha.113.02217_references_DOI_PWDbkUTySA9tl5S0HNPCLnxAuN2"},{"@type":"CROSSREF","@value":"10.1007/s10157-013-0803-y_references_DOI_PWDbkUTySA9tl5S0HNPCLnxAuN2"},{"@type":"CROSSREF","@value":"10.1007/s10157-013-0893-6_references_DOI_PWDbkUTySA9tl5S0HNPCLnxAuN2"},{"@type":"CROSSREF","@value":"10.1038/s41440-018-0037-1_references_DOI_PWDbkUTySA9tl5S0HNPCLnxAuN2"},{"@type":"CROSSREF","@value":"10.3390/ijms140815361_references_DOI_PWDbkUTySA9tl5S0HNPCLnxAuN2"},{"@type":"CROSSREF","@value":"10.1097/hjh.0b013e328338bb11_references_DOI_PWDbkUTySA9tl5S0HNPCLnxAuN2"},{"@type":"CROSSREF","@value":"10.4264/numa.73.14_references_DOI_PWDbkUTySA9tl5S0HNPCLnxAuN2"},{"@type":"CROSSREF","@value":"10.1248/bpb.b19-00057_references_DOI_PWDbkUTySA9tl5S0HNPCLnxAuN2"}]}